Methylin

Methylin = Ritalin IR with a different label on the bottle. Mallinckrodt's brand of racemic methylphenidate IR (chewable tablets + oral solution + standard tablets). Pharmacokinetically and clinically identical to Ritalin IR — the only differentiators are (1) the chewable + liquid formulations (pediatric-friendly) and (2) Mallinckrodt manufacturing rather than Novartis. Verdict for Dylan tracks Ritalin one-for-one: SKIP-FOR-NOW for daily, OPTIONAL-ADD as PRN tool if clinical ADHD diagnosis ever opens Schedule II Rx access. See ritalin.md for the full mechanism, evidence, dosing, side-effect, and decision-matrix discussion — this file documents Methylin-specific details only.

Methylin is methylphenidate IR. There is no mechanistic distinction from Ritalin IR. Mallinckrodt simply manufactures and brands the same molecule under the Methylin trade name. Mechanism summary:

• Racemic d/l-threo-methylphenidate — competitive DAT + NET reuptake inhibitor; d-isomer carries ~all CNS activity, l-isomer ~10× weaker and ~95% presystemically hydrolyzed by CES1A1.
• Not a releaser (key MPH-class vs amphetamine distinction): no TAAR1 agonism, no VMAT2 reverse-pumping. Effect ceiling constrained by endogenous firing.
• Metabolism: CES1A1-mediated de-esterification to inactive ritalinic acid. Minimal CYP involvement.
• Half-life ~2-3 hr (d-MPH); clinical effect window ~3-4 hr; Tmax 1-2 hr.

Methylin formulation portfolio (the actual differentiator):

• Methylin tablets: 5, 10, 20 mg standard IR tablets. Identical PK to Ritalin IR tablets.
• Methylin chewable tablets: 2.5, 5, 10 mg grape-flavored chewables. Bioequivalent to swallowed tablets when chewed and washed down with water (must be co-administered with at least 8 oz of water — chewing alone without fluid produces lower exposure).
• Methylin oral solution: 5 mg/5 mL and 10 mg/5 mL grape-flavored liquid. Bioequivalent to tablets on AUC; slightly faster Tmax (~30-45 min vs 60-90 min for tablets) due to liquid dissolution.
• PK note for chewable + solution: FDA bioequivalence studies confirm AUC equivalence to standard tablets but the liquid form has marginally faster absorption — relevant for pediatric titration but not for cognitive enhancement use cases.

For Dylan: the formulation differences are clinically irrelevant — adult cognitive enhancement use of MPH-IR doesn't benefit from chewables or oral solution over standard tablets. The chewable/liquid forms exist because pediatric ADHD patients often can't or won't swallow standard tablets. If Methylin ever showed up in Dylan's medicine cabinet, the standard 10mg tablet would be the only formulation worth using.

See ritalin.md "Mechanism" section for full d/l-isomer pharmacology, l-isomer presystemic clearance debate, and CES1 metabolism deep-dive.